"We report to our knowledge the first clinical data on a PI3 kinase plus BTK inhibitor doublet in B cell malignancies. The preliminary efficacy results certainly show a high response rate," said lead investigator Matthew S. Davids, MD, Department of Medical Oncology, Dana-Farber Cancer Institute. "This approach of dual targeting the B cell receptor pathway is potentially a feasible strategy."
onclive.com/conference-cove...
Jeff
As one of the CLL data points in that study, I can confirm that TGR-1202 is working for me with much less toxicity than Idelalisib had for me. The ibrutinib part of the dual attack on B cell signaling has been much tougher for me- bleeding and Afib problems.
John
John,
Sorry to hear that. Will they let you continue and see if those AE subside?
Jeff
Yes, I have been on a reduced dose of Ibrutinib for about six months so I am still in the trial. Tweaking rhythm control meds for the A-fin and no further bleeding problems
Excellent. MDA has a trial on lower doses of ibrutinib now as some feel the dose is too high.
Steady as she goes.
Jeff
High CLL IN BONE MARROW
Cll improvement on Ibrutinib 
Stopping ibrutinib and imaging in CLL
